# US 2026/0242746 A1 · Methods of cell preservation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242746 A1
- Document ID: US20260242746A1
- Status: Published application
- Kind: A1
- Application number: 19/156,290
- Filed: 2024-02-14
- Published: 2026-08-20
- Earliest claimed: 2023-02-14
- Assignees: Be Biopharma, Inc.
- Applicants: Be Biopharma, Inc.
- Inventors: Mark Louis Lalli; Jordan Marie Smelker
- Web page: https://patentgrep.com/patent/US20260242746A1

## CPC

- A01N 1/125: Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
- C12N 5/525: {Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- C12N 5/0635: {B lymphocytes}
- C12N 2510/00: Genetically modified cells
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides methods and compositions for culturing, cryopreserving, and administering engineered B lineage cell populations. The methods and compositions are provided herein.

## Claims

### Claim 1

A method of preparing a B lineage cell population for cryopreservation, the method comprising a step of:
contacting the B lineage cell population with cryopreservation media comprising:
about 4.5% to about 5% DMSO; and
about 2.5% to about 10% HSA;
thereby producing a cryopreservation cell preparation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cryopreservation cell preparation undergoes controlled cooling in a controlled cooling chamber, comprising one or more steps of:
(i) cooling the chamber until the cryopreservation cell preparation reaches 4° C.;
(ii) cooling the chamber at a rate of 1° C./minute until the cryopreservation cell preparation reaches −4° C.;
(iii) cooling the chamber at a rate of 25° C./minute until the chamber reaches −40° C.;
(iv) heating the chamber at a rate of 10° C./minute until the chamber reaches −12° C.;
(v) cooling the chamber at a rate of 1° C./minute until the chamber reaches −40° C.;
(vi) cooling the chamber at a rate of 10° C./minute until the chamber reaches −90° C.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the B lineage cell population is or comprises a population of genetically modified plasma cells.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2, wherein the B lineage cell population is or comprises a population of plasmablasts.

### Claim 5 (depends on 4)

The method of claim 4, wherein the B lineage cell population is or comprises a population of plasma cell precursors.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the cryopreservation media comprises 5% DMSO.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the cryopreservation media comprises 2.5% HSA.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the cryopreservation cell preparation maintains at least 50% viability after being frozen for at least 24 hours.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cryopreservation cell preparation maintains at least 50% viability after being frozen for one week.

### Claim 10 (depends on 8)

The method of claim 8, wherein the cryopreservation cell preparation maintains at least 50% viability after being frozen for one month.

### Claim 11 (depends on 8)

The method of claim 8, wherein the cryopreservation cell preparation maintains at least 50% viability after being frozen for six months.

### Claim 12

A composition comprising:
(i) a population of frozen, genetically modified B lineage cells; and
(ii) cryopreservation media comprising:
about 4.5% to about 5% DMSO; and
about 2.5% to about 10% HSA.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the cryopreservation media comprises 5% DMSO.

### Claim 14 (depends on 12, 13)

The composition of claim 12 or 13, wherein the cryopreservation media comprises 2.5% HSA.

### Claim 15 (depends on 12, 13, 14)

The composition of any one of claims 12-14, wherein the transgene is Factor IX.

### Claim 16 (depends on 12, 13, 14, 15)

The composition of any one of claims 12-15, wherein the endogenous gene locus is CCR5 or JCHAIN.

### Claim 17 (depends on 12, 13, 14, 15, 16)

The composition of any one of claims 12-16, wherein the genetically modified B lineage cells have been frozen for at least 24 hours and maintain at least 50% viability after thawing.

### Claim 18 (depends on 12, 13, 14, 15, 16, 17)

The composition of any one of claims 12-17, wherein the genetically modified B lineage cells have been frozen for at least 24 hours and at least 25% of cells secrete IgG after thawing.

### Claim 19 (depends on 12, 13, 14, 15, 16, 17, 18)

The composition of any one of claims 12-18, wherein the genetically modified B lineage cells have been frozen for at least 24 hours and at least 25% of cells express IgM after thawing.

### Claim 20 (depends on 12, 13, 14, 15, 16, 17, 18, 19)

The composition of any one of claims 12-19, wherein the population has been frozen for at least one week.

### Claim 21 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20)

The composition of any one of claims 12-20, wherein the population has been frozen for at least one month.

### Claim 22 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The composition of any one of claims 12-21, wherein the population has been frozen for at least six months.

### Claim 23

A method of treating a patient for a disease, wherein the method comprises administering a population of genetically modified B lineage cells that have been cryopreserved.

### Claim 24 (depends on 23)

The method of claim 23, wherein the population of genetically modified B lineage cells have been cryopreserved in media comprising about 4.5% to about 5% DMSO and about 2.5% to about 10% HSA and thawed prior to administration to a patient.

### Claim 25 (depends on 24)

The method of claim 24, wherein the media comprises 5% DMSO.

### Claim 26 (depends on 23, 24, 25)

The method of any one of claims 23-25, wherein the media comprises 2.5% HSA.
